Navigation Links
Misonix Reports First Quarter Fiscal 2011 Financial Results
Date:11/12/2010

FARMINGDALE, N.Y., Nov. 12, 2010 /PRNewswire-FirstCall/ -- Misonix, Inc. (Nasdaq: MSON), a developer of state of the art, ultrasonic medical device technology, which worldwide is used for acute health conditions, today reported financial results for the first fiscal quarter ending September 30, 2010.  Michael A. McManus, Jr., President and Chief Executive Officer, and Richard Zaremba, Senior VP and Chief Financial Officer, will host a conference call Monday, November 15, 2010 at 4:30 pm to discuss the Company's first fiscal quarter results.

The Company also reported the following financial and operational achievements:

  • A 24% increase in revenue for the first fiscal quarter 2011 compared with the first fiscal quarter 2010
  • Medical device products revenue for the first fiscal quarter 2011 increased 34% to $2.7 million compared with the first fiscal quarter 2010
  • Gross profit as a percentage of revenues increased to 50.3% in the first fiscal quarter 2011

  • Revenues for the three months ended September 30, 2010 were $3.3 million, a 24% increase when compared with $2.6 million for the same period in fiscal 2010.  Medical device product sales increased $689,000 or 34% to $2.7 million and laboratory and scientific product sales decreased $62,000 to $566,000 for the three months ended September 30, 2010.  The increase in revenue for medical device products during the three months ended September 30, 2010 was primarily attributable to sales of the Company's BoneScalpel™, Neuroaspirator, AutoSonix™ and SonicOne® products.

    Gross profit as a percentage of sales increased to 50.3% for the three months ended September 30, 2010 from 38.4% for the three months ended September 30, 2009.  Gross profit for medical device products increased to 54.7% for the three months ended September 30, 2010 from 45.4% for the three months ended September 30, 2009.  Gross profit for laboratory and scientific products increased to 29.1% for the three months ended September 30, 2010 from 16% for the three months ended September 30, 2009.

    The Company reported a net loss from continuing operations of $842,531 or $.12 per share for the three months ended September 30, 2010 compared with a loss of $1.2 million or $.18 per share for the same period in fiscal 2010.  The Company reported a net loss attributable to Misonix, Inc. shareholders for the three months ended September 30, 2010 of $1.0 million or $.15 per share which included a loss from discontinued operations of $175,000 or $.03 per share compared to a net loss of $895,000 or $.13 per share attributable to Misonix, Inc. shareholders which included income from discontinued operations of $352,000 or $.05 per share for the three months ended September 30, 2009.

    Commenting on Misonix's financial and operating results, Michael A. McManus, Jr., President and Chief Executive Officer, said, "We are pleased by both the revenue and gross margin increases in our medical device products for this quarter.   We have made significant cost reductions and we should see the full impact of those in our second fiscal quarter.  We continue to maintain a strong cash balance with no borrowings.

    "Our recent acquisition of the Aesculap Neuroaspirator business gives us the opportunity to grow this business using our salesforce and the Misonix brand.  Margins from this business are expected to increase from direct sales and the disposables revenue stream. We are also encouraged by the revenue growth of the BoneScalpel and SonicOne and are optimistic about this trend.

    "We are continuing to build out our sales distribution network having recently added strong partners in China, Russia and the Middle East. Also, we continue to look at opportunities to increase our growth from potential acquisitions and the distribution of add on products to those being sold to our present customers."

    Conference Call:Misonix management will host a conference call and webcast on Monday, November 15, 2010 at 4:30 pm to discuss first quarter results.

    Shareholders and other interested parties may participate in the conference call by dialing (800) 706-7741 (domestic) or (617) 614-3471 (international) and entering access code 84227160, a few minutes before the start of the call. A simultaneous webcast will be available via Misonix's website at www.misonix.com. The call will be archived on the company's website for at least 90 days.

    A recording of the live-call will be available approximately 2 hours after the event through November 22, 2010. The dial-in number to listen to the recording is (888) 286-8010 or (617) 801-6888. The replay access code is 31342240.

    About Misonix:Misonix, Inc. (Nasdaq: MSON) designs, develops, manufactures and markets therapeutic ultrasonic medical devices and laboratory equipment.  Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies.  Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications.  Additional information is available on the Company's Web site at www.misonix.com.

    With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995.  These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances.  Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships,  regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.  The Company disclaims any obligation to update its forward-looking relationships.MISONIX, INC. And Subsidiaries Consolidated Balance SheetsSeptember 30, 2010June 30, 2010AssetsCurrent Assets:  Cash and cash equivalents

    $9,413,437$9,900,605  Accounts receivable, less allowancefor doubtful accounts of $109,178 and$123,346, respectively

    1,920,6892,335,653  Inventories, net

    2,919,2432,699,717  Prepaid expenses and other current assets

    362,283515,427  Note receivable

    920,1451,075,105Total current assets

    15,535,79716,526,507Property, plant and equipment, net

    526,084500,215Goodwill

    1,701,0941,701,094Other assets

    1,464,8041,730,339Total assets

    $19,227,779$20,458,155Liabilities and stockholders' equityCurrent liabilities:  Notes payable

    $84,491$177,679  Accounts payable

    832,940888,654  Accrued expenses and other current liabilities

    915,7041,000,523Total current liabilities

    1,833,1352,066,856Capital lease obligations

    10,47414,274Deferred income

    214,420250,739Deferred lease liability

    1,404-Total liabilities

    2,059,4332,331,869Commitments and contingenciesStockholders' equity:  Capital stock, $0.01 par value - shares authorized 20,000,000; 7,079,169  issued and 7,001,369 outstanding, respectively

    70,79270,792  Additional paid-in capital

    25,562,82325,502,717  Accumulated deficit

    (8,052,645)(7,034,799)  Treasury stock, 77,800 shares

    (412,424)(412,424)Stockholders' equity

    17,168,54618,126,286Total liabilities and Stockholders' equity

    $19,227,979$20,458,155MISONIX, INC. And SubsidiariesConsolidated Statements of OperationsUnauditedThree Months EndedSeptember 30,2010

    2009Net sales

    $3,257,988

    $2,631,017Cost of goods sold

    1,620,703

    1,621,893Gross profit

    1,637,285

    1,009,124Selling expenses

    965,007

    919,607General and administrative expenses

    1,217,805

    1,312,680Research and development expenses

    460,494

    422,469Total operating expenses

    2,643,306

    2,654,756Operating loss from continuing operations

    (1,006,021)

    (1,645,632)Total other income

    201,590

    152,724Loss from continuing operations before  income taxes

    (804,431)

    (1,492,908)Income tax (benefit)

    38,100

    (245,764)Net loss from continuing operations

    (842,531)

    (1,247,144)Discontinued operations:Net (loss) income from discontinued operations, net of income tax expense of $0, and $470,397

    (175,315)

    527,493Net loss from sale of discontinued operations, net of income tax expense of $0 and $957,937

    -

    (195,716)Noncontrolling interest in discontinued operations net of income taxes

    -

    20,255Net (loss) income from discontinued operations

    (175,315)

    352,032Net loss attributable to Misonix, Inc. shareholders

    ($1,017,846)

    ($895,112)Net loss per share from continuing operations attributable to Misonix, Inc. shareholders-Basic

    ($0.12)

    ($0.18)Net (loss) income per share from discontinued operations-Basic

    (0.03)

    0.05Net loss per share attributable to Misonix, Inc. shareholders-Basic

    ($0.15)

    ($0.13)Net loss per share from continuing operations attributable to Misonix, Inc. shareholders-Diluted

    ($0.12)

    ($0.18)Net (loss) income per share from discontinued operations-Diluted

    (0.03)

    0.05Net loss per share attributable to Misonix, Inc. shareholders-Diluted

    ($0.15)

    ($0.13)Weighted average common shares-basic

    7,001,369

    7,001,369Weighted average common shares-diluted

    7,001,369

    7,001,369Investor Relations Contact:Kevin McGrath / Cameron Associates, Inc.212-245-4577Kevin@cameronassoc.com
    '/>"/>

    SOURCE Misonix, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Misonix Schedules Fourth Quarter and Fiscal Year 2009 Financial Results Conference Call; October 1, 2009 at 4:30 p.m. Eastern
    2. Misonix Reports Fourth Quarter and Fiscal Year 2009 Financial Results
    3. Misonix, Inc. Announces the Sale of Sonora Medical Systems for $8 Million
    4. Misonix Announces New Distribution Agreement for United Kingdom and Republic of Ireland
    5. Misonix Announces New Distribution Agreement for Mexico
    6. Misonix Schedules First Quarter 2010 Financial Results Conference Call; November 16, 2009 at 4:30 p.m. Eastern
    7. Misonix Announces New Distribution Agreement for Saudi Arabia and Other Middle Eastern Countries
    8. Misonix Announces New Distribution Agreement for Peru
    9. Misonix Announces New Distribution Agreement For The United Arab Emirates (UAE)
    10. Misonix Announces New Distribution Agreement for Argentina
    11. Misonix Announces New Distribution Agreement for Kingdom of Saudi Arabia
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/5/2016)... Ala. , Feb. 5, 2016  Patients in ... high intensity focused ultrasound (HIFU) therapy no longer have to ... to announce its partnership with Urology Centers of Alabama ... the newly FDA-cleared procedure for qualifying patients. ... their expertise in the treatment of prostate cancer using many ...
    (Date:2/5/2016)... February 5, 2016 --> ... report states that the global active pharmaceuticals ingredients (APIs) ... predicted to reach US$185.9 bn by 2020. It is ... 2014 to 2020. The title of the report is ... by Geography, and by Therapeutic Area) - Global Industry ...
    (Date:2/5/2016)... -- Site Profile: --> ... Speech Recognition People, announced their latest primary healthcare case study where ... turnaround times and to save the practice money. Site ... Challenge: --> ,- Wirral CCG ,- VoicePower ... doctors ,- Wirral CCG ,- VoicePower client since 2013 ...
    Breaking Medicine Technology:
    (Date:2/5/2016)... Falls, NY & Salt Lake City, UT (PRWEB) , ... February ... ... Davis, Founder of Activz Whole-Food Nutrition , announced that the much-anticipated feature with ... on the New Really Cool Humans Amateur TV Network. , Each week, on his ...
    (Date:2/5/2016)... York, New York (PRWEB) , ... February 05, 2016 , ... ... life? The answer may be at the tips of your toes. Foot massage, whether ... as well as pure comfort and relaxation. The American Board of Multiple Specialties ...
    (Date:2/5/2016)... Chicago, Illinois (PRWEB) , ... February 05, 2016 ... ... advisors and independent PROSHRED franchises from across the country gathered at the La ... to recognize top performers. PROSHRED Chicago was named the year’s most outstanding ...
    (Date:2/5/2016)... ... February 05, 2016 , ... Pivot Point ... Best in KLAS: Software & Services for HIT Implementation Support & Staffing report ... independently ranks vendor performance by healthcare executives, managers and clinicians representing over 4,500 ...
    (Date:2/5/2016)... Viejo, CA (PRWEB) , ... February 05, 2016 , ... ... X. Move from on one drop zone to the next using Colorize's dynamic moving ... complements any project. This package includes a 3D slideshow environment with 1 to 5 ...
    Breaking Medicine News(10 mins):